CClinicalTrials.gg
Active, not recruitingNCT05049967iKnowUpdated Apr 30, 2024

iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders

An observational study in Genetic Disease, sponsored by Illumina, Inc.. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Illumina, Inc. · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
150
Sex
All
01

Study summary

Prospective observational study to further understand the value that a multi-omic approach has in individuals with a multi system, early onset disorder that does not have a molecular diagnosis by whole genome sequencing.

Read the detailed description

Understand the value and utilization of integrated multi-omics, in multi-system early onset disorders that have failed to yield findings by whole genome sequencing

02

Conditions studied

  • Genetic Disease
03

In context

Genetic Diseases, Inborn

403 studies on the registry are indexed under Genetic Diseases, Inborn; 145 are open to participants now.

This study's planned enrollment of 150 is below the median of 192 across 195 observational studies indexed under Genetic Diseases, Inborn.

Browse Genetic Diseases, Inborn studies →

Lead sponsor

Illumina, Inc. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Outpatient setting with eighty percent consisting of prior negative genome cases that have previously received a clinical whole genome sequencing (cWGS) test. Remaining twenty percent will be positive controls who previously have a definitive diagnosis from clinical genetic testing.

Inclusion criteria

  • Undiagnosed probands must meet all of the following:

    1. Must be able to understand and sign an informed consent and speak, read, and write in their native language (if the subject is a minor, their parent must have these abilities)
    2. Proband between the ages of 12 months and 65 years
    3. Study consent and participation of at least two unaffected family members (biological parents preferred. One biological parent and unaffected sibling allowed)
    4. If applicable, unaffected sibling must be between the ages of 12 months and 65 years
    5. A high prior probability of a multi-system early onset undiagnosed genetic disorder based on an expert medical assessment
    6. Clinical WGS that did not yield a definitive diagnosis
    7. It is preferred but not required that ancestry is from an under-represented population in current clinical genetic and translational research data repositories, especially African American, Asian American and Native American
    8. Must be willing to have blood, urine and fecal samples taken to include participating family members

Diagnosed probands must meet all of the following:

  1. Must be able to understand and sign an informed consent and speak, read, and write in their native language (if the subject is a minor, its Parent or Legally Authorized Representative must have these abilities).
  2. Proband between the ages of 12 months and 65 years
  3. Study consent and participation of at least two unaffected family members (biological parents preferred. One biological parent and unaffected sibling allowed)
  4. If applicable, unaffected sibling must be between the ages of 12 months and 65 years
  5. Known genetic cause(s) of disease, disorder, or phenotypic defect through prior clinical whole genome sequencing
  6. It is preferred but not required that ancestry is from an under-represented population in current clinical genetic and translational research data repositories, especially African American, Asian American and Native American
  7. Must be willing to have blood, urine and fecal samples taken to include participating family members

Exclusion criteria

Exclusion Criteria:

  • Undiagnosed probands must not meet any:

    1. Known non-genetic cause(s) of disease, disorder, or phenotypic defect
    2. Principal Investigator decides that the study is not in the best interest of the proband

Diagnosed probands must not meet any:

  1. Principal Investigator decides that the study is not in the best interest of the proband
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Based on analysis of data from completed clinical utility evaluation surveys following receipt of study results by the PI, assess whether a patient's change of management resulted from the multi-omic results

    Understand the value and utilization of integrated multi-omics, in multi-system early onset disorders that have failed to yield findings by whole genome sequencing

    Time frame: 120 Days

Secondary outcomes

  1. Number of diagnoses yielded by each of the different orthogonally confirmed assay results

    Assess the number of new diagnoses yielded by each approach

    Time frame: 120 Days

  2. Analyze data from completed clinical utility evaluation surveys; number of patients with change of management and whether the change was due to a diagnosis yielded by multiomic results

    Analyze the clinical utility derived from a diagnosis

    Time frame: 120 Days

  3. Data utilization of multi-omic dataset for scientific community

    Establish a multi-omic reference dataset from resource limited populations that can be used by the scientific community

    Time frame: 120 Days

07

Study locations

1 site
  • Clinic for Special Children
    Strasburg, Pennsylvania 17579, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05049967
Lead sponsor
Illumina, Inc.
Collaborators
Medical College of Wisconsin
Responsible party
Sponsor
First posted
Sep 20, 2021
Start date
Nov 9, 2021
Primary completion
Dec 10, 2021
Completion
Dec 31, 2024 (estimated)
Last update
Apr 30, 2024

Study contacts

Ali Crawford, PhD
study director · Illumina, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion